Subtype
Pancreatic Neuroendocrine Neoplasm
CI-CAN-00001357Explore in graph →
Non-malignant37 active trials1 evidence items
- NCIt
- C27031
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001357Explore in graph →
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | active not recruiting | Phase 2 | 34 | TaiRx, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05040360 | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 141 | SWOG Cancer Research NetworkNETWORK | 3 | Dec 15, 2025 | clinicaltrials |
| NCT02159989 |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
| completed |
| Phase 1 |
| 83 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Oct 20, 2025 |
| clinicaltrials |
| NCT07121478 | Patients With High-grade Pancreatic Neuroendocrine Tumors | enrolling by invitation | Phase 2 | 46 | National Cancer Center, KoreaOTHER_GOV | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06121622 | Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours(3DPanNET) | recruiting | — | 70 | IRCCS San RaffaeleOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT02230176 | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II(OCCLURANDOM) | completed | Phase 2 | 84 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT02842749 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | completed | Phase 4 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | terminated | Phase 2 | 11 | Roswell Park Cancer InstituteOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06592989 | A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET | recruiting | — | 20 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT05568017 | Neoadjuvant PRRT With Y-90-DOTATOC in pNET(NeoNet) | terminated | Phase 2 | 11 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06024343 | Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction | completed | N/A | 230 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06557408 | Pancreatic Fistula After Minimally Invasive Enucleation | completed | — | 173 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06041009 | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations | recruiting | — | 2,100 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02021604 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | recruiting | Phase 1 | 250 | Cook Children's Health Care SystemOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06246630 | In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor | unknown | N/A | 20 | Ruijin HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05476978 | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions | completed | — | 130 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03084770 | Asymptomatic Small Pancreatic Endocrine Neoplasms.(ASPEN) | unknown | — | 1,000 | IRCCS San RaffaeleOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04452396 | CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia | terminated | N/A | 7 | Barts & The London NHS TrustOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06167421 | Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy | not yet recruiting | N/A | 240 | Fudan UniversityOTHER | 0 | Dec 12, 2023 | clinicaltrials |
| NCT02264665 | OPALINE : A Study Of Morbidity And Mortality At 2 Years(OPALINE) | completed | — | 144 | PfizerINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05523778 | A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct | unknown | N/A | 78 | Peking Union Medical College HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06080204 | Real-world Study on Adjuvant Octreotide Therapy in pNETs | completed | N/A | 411 | Changhai HospitalOTHER | 0 | Oct 18, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04979611 | The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | unknown | Phase 1 | 60 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05907824 | Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm | unknown | — | 800 | Fudan UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05171517 | Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy | completed | — | 200 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05243082 | Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms(ERFA-PNET) | recruiting | N/A | 20 | Oslo University HospitalOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03918759 | Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs | completed | — | 100 | IRCCS San RaffaeleOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04915144 | 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | withdrawn | Phase 2 | 0 | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05034783 | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05566093 | EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors | unknown | N/A | 20 | Guangxi Medical UniversityOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05554744 | EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors | unknown | N/A | 20 | Guangxi Medical UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04483349 | Assessment of What Patients and Healthcare Providers Value | completed | — | 397 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT01229943 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | completed | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2022 | clinicaltrials |
| NCT02358356 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study(CONTROL NETS) | completed | Phase 2 | 75 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03741517 | Biomarker Study of Pancreatic Neuroendocrine Tumours | unknown | — | 40 | Uppsala UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02586844 | Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors(NET-SEQ) | completed | — | 13 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05316480 | Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Dec 23, 2025source: clinicaltrials